Dr. Welling on CheckMate-040 Trial of Nivolumab in HCC

Theodore H. Welling, MD
Published Online: Sunday, Sep 17, 2017



Theodore H. Welling, MD, associate professor of surgery, director of the Liver Tumor Program at Perlmutter Cancer Center of NYU Langone Medical Center, discusses the purpose of the CheckMate-040 trial, which explored nivolumab (Opdivo) in patients with hepatocellular carcinoma. (HCC).

The phase I/II trial demonstrated the safety and efficacy findings of nivolumab in patients who were previously exposed to sorafenib (Nexavar) and failed or ultimately progressed on sorafenib versus patients who were naïve to sorafenib, Welling explains. Currently, sorafenib is the only medicine approved for the frontline treatment of patients with HCC.

The anti—PD-1 inhibitor nivolumab is designed to block the PD-1 pathway, allowing the immune system theoretically to increase its response—or at least have a return of response—in what could otherwise be exhausted immune cells, Welling adds.

Brought to you in part by Eisai


Theodore H. Welling, MD, associate professor of surgery, director of the Liver Tumor Program at Perlmutter Cancer Center of NYU Langone Medical Center, discusses the purpose of the CheckMate-040 trial, which explored nivolumab (Opdivo) in patients with hepatocellular carcinoma. (HCC).

The phase I/II trial demonstrated the safety and efficacy findings of nivolumab in patients who were previously exposed to sorafenib (Nexavar) and failed or ultimately progressed on sorafenib versus patients who were naïve to sorafenib, Welling explains. Currently, sorafenib is the only medicine approved for the frontline treatment of patients with HCC.

The anti—PD-1 inhibitor nivolumab is designed to block the PD-1 pathway, allowing the immune system theoretically to increase its response—or at least have a return of response—in what could otherwise be exhausted immune cells, Welling adds.

Brought to you in part by Eisai



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesJan 30, 20182.0
Medical Crossfire®: The Expanding Role of PARP Inhibitors in the Treatment of Ovarian Cancers – Current Strategies and Future DirectionJan 30, 20181.5
Publication Bottom Border
Border Publication
x